United Therapeutics (UTHR) Research & Development (2016 - 2025)
Historic Research & Development for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to $127.5 million.
- United Therapeutics' Research & Development rose 2318.84% to $127.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $544.3 million, marking a year-over-year increase of 916.57%. This contributed to the annual value of $481.0 million for FY2024, which is 1789.22% up from last year.
- As of Q3 2025, United Therapeutics' Research & Development stood at $127.5 million, which was up 2318.84% from $134.0 million recorded in Q2 2025.
- Over the past 5 years, United Therapeutics' Research & Development peaked at $303.7 million during Q1 2021, and registered a low of $66.1 million during Q3 2022.
- Its 5-year average for Research & Development is $113.8 million, with a median of $93.9 million in 2022.
- In the last 5 years, United Therapeutics' Research & Development soared by 31489.07% in 2021 and then crashed by 7728.02% in 2022.
- Over the past 5 years, United Therapeutics' Research & Development (Quarter) stood at $82.9 million in 2021, then rose by 13.27% to $93.9 million in 2022, then skyrocketed by 61.24% to $151.4 million in 2023, then fell by 11.62% to $133.8 million in 2024, then dropped by 4.71% to $127.5 million in 2025.
- Its Research & Development was $127.5 million in Q3 2025, compared to $134.0 million in Q2 2025 and $149.0 million in Q1 2025.